Swiss National Bank Amicus Therapeutics, Inc. Transaction History

Swiss National Bank

$150 Billion
Q3 2024

A detailed history of Swiss National Bank transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Swiss National Bank holds 434,300 shares of FOLD stock, worth $4.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

434,300

Previous 434,300 -0.0%

Holding current value

$4.22 Million

Previous $4.31 Million 7.66%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$11.43 - $14.24 $113,157 - $140,976	9,900 Added 2.33%	434,300 $5.12 Million
Q4 2023 Feb 06, 2024	SELL	$9.97 - $14.52 $446,656 - $650,496	-44,800 Reduced 9.55%	424,400 $6.02 Million
Q3 2023 Nov 08, 2023	BUY	$11.78 - $13.86 $89,528 - $105,336	7,600 Added 1.65%	469,200 $5.71 Million
Q2 2023 Aug 09, 2023	BUY	$10.72 - $13.3 $72,896 - $90,440	6,800 Added 1.5%	461,600 $5.8 Million
Q1 2023 May 10, 2023	SELL	$10.91 - $13.54 $580,412 - $720,328	-53,200 Reduced 10.47%	454,800 $5.04 Million
Q4 2022 Feb 08, 2023	BUY	$9.89 - $12.7 $95,933 - $123,190	9,700 Added 1.95%	508,000 $6.2 Million
Q3 2022 Nov 09, 2022	BUY	$9.82 - $12.75 $35,352 - $45,900	3,600 Added 0.73%	498,300 $5.2 Million
Q2 2022 Aug 09, 2022	SELL	$6.23 - $11.12 $201,852 - $360,288	-32,400 Reduced 6.15%	494,700 $5.31 Million
Q1 2022 May 09, 2022	BUY	$7.89 - $12.48 $448,152 - $708,864	56,800 Added 12.08%	527,100 $4.99 Million
Q3 2021 Nov 08, 2021	BUY	$8.74 - $11.84 $36,708 - $49,728	4,200 Added 0.9%	470,300 $4.49 Million
Q2 2021 Aug 06, 2021	SELL	$8.71 - $10.72 $607,958 - $748,256	-69,800 Reduced 13.02%	466,100 $4.49 Million
Q1 2021 May 07, 2021	BUY	$9.2 - $23.86 $85,560 - $221,898	9,300 Added 1.77%	535,900 $5.3 Million
Q4 2020 Feb 05, 2021	BUY	$13.47 - $24.89 $13,470 - $24,890	1,000 Added 0.19%	526,600 $12.2 Million
Q3 2020 Nov 09, 2020	SELL	$12.89 - $15.89 $556,848 - $686,448	-43,200 Reduced 7.59%	525,600 $7.42 Million
Q2 2020 Aug 05, 2020	BUY	$8.86 - $15.69 $660,956 - $1.17 Million	74,600 Added 15.1%	568,800 $8.58 Million
Q1 2020 May 08, 2020	BUY	$6.63 - $11.16 $45,084 - $75,888	6,800 Added 1.4%	494,200 $4.57 Million
Q4 2019 Feb 06, 2020	BUY	$7.48 - $10.75 $398,684 - $572,975	53,300 Added 12.28%	487,400 $4.75 Million
Q3 2019 Nov 12, 2019	BUY	$8.02 - $13.25 $143,558 - $237,175	17,900 Added 4.3%	434,100 $3.48 Million
Q2 2019 Aug 02, 2019	BUY	$10.96 - $14.4 $780,352 - $1.03 Million	71,200 Added 20.64%	416,200 $5.19 Million
Q1 2019 May 10, 2019	BUY	$10.04 - $13.92 $106,423 - $147,552	10,600 Added 3.17%	345,000 $4.69 Million
Q4 2018 Feb 13, 2019	BUY	$8.38 - $13.44 $47,766 - $76,608	5,700 Added 1.73%	334,400 $3.2 Million
Q3 2018 Nov 08, 2018	BUY	$11.6 - $16.54 $67,280 - $95,932	5,800 Added 1.8%	328,700 $3.97 Million
Q1 2018 May 04, 2018	BUY	$13.76 - $17.12 $972,832 - $1.21 Million	70,700 Added 28.03%	322,900 $4.86 Million
Q4 2017 Feb 07, 2018	BUY	$12.51 - $16.24 $148,869 - $193,255	11,900 Added 4.95%	252,200 $3.63 Million
Q3 2017 Nov 03, 2017	BUY	$11.74 - $15.78 $2.82 Million - $3.79 Million	240,300	240,300 $3.62 Million

Others Institutions Holding FOLD

# of Institutions

313

Shares Held

314M

Call Options Held

516K

Put Options Held

833K

View Full List

About AMICUS THERAPEUTICS, INC.

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.73B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

More about FOLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Amicus Therapeutics, Inc. Transaction History